Bone Marrow Research / 2012 / Article / Tab 3 / Clinical Study
Occurrence and Impact of Minor Histocompatibility Antigens' Disparities on Outcomes of Hematopoietic Stem Cell Transplantation from HLA-Matched Sibling Donors Table 3 Patients characteristics (
).
Median ( range ) Quartiles Age (years) Donor 35 (14–60) 26–49 Recipient 38 (14–59) 28–47 Time from diagnosis to allo-HCT (years) 0.62 (0.24–12.91) 0.5–1.12
% Sex Donor Male 32 51.6 Female 30 48.4 Recipient Male 28 45.2 Female 34 54.8 Donor/recipient Male/male 16 25.8 Female/female 18 29 Male/female 16 25.8 Female/male 12 19.4 Compatibility of ABO blood groups Compatible 36 58.1 Minor incompatibility 8 12.9 Major incompatibility 14 22.5 Minor and major incompatibility 4 6.5 Diagnosis AML 45 72.5 ALL 14 22.5 CML 1 1.61 MDS 1 1.61 NHL 1 1.61 Regimen TBI + cyclophosphamide 12 19.35 Chemotherapy Busulfan + cyclophosphamide 33 53.2 Treosulfan + fludarabine 13 20.96 Busulfan + fludarabine 2 3.22 Treosulfan + cyclophosphamide 2 3.22 Source of hematopoietic cells Bone marrow 40 64.5 Peripheral blood 10 16.1 Bone marrow and peripheral blood 12 19.4 Median (range) Quartiles Number of transplanted cells Nucleated cells (NC)
10
8/kg 3.51 (0.12–72.15) 2.34–5.84 CD34(+)
10
6/kg 2.77 (0.95–10.50) 1.68–4.19 CD3(+)
10
7/kg 3.84 (0.20–46.90) 2.71–18.01 Time range of allo-HCT 01.2000–12.2008